Multiple Myeloma Prognosis (R-ISS)
Revised international staging system for myeloma
The Revised International Staging System (R-ISS) includes variables included in the original ISS (serum beta-2 microglobulin and serum albumin), while also including the additional prognostic information obtained from serum LDH and high-risk chromosomal abnormalities detected by interphase fluorescent in situ hybridization (iFISH) after CD138 plasma cell purification.
The revised ISS stages are as follows:
- Stage I: ISS stage I and standard-risk CA by iFISH and normal LDH
- Stage II: Not R-ISS stage I or III
- Stage III: ISS stage III and either high-risk CA by iFISH or high LDH
- [1]Palumbo A et al.: Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2015 September 10, 33 (26): 2863-9
Results
Real-time automated computation
The Revised International Staging System (R-ISS) includes variables included in the original ISS (serum beta-2 microglobulin and serum albumin), while also including the additional prognostic information obtained from serum LDH and high-risk chromosomal abnormalities detected by interphase fluorescent in situ hybridization (iFISH) after CD138 plasma cell purification.
The revised ISS stages are as follows:
- Stage I: ISS stage I and standard-risk CA by iFISH and normal LDH
- Stage II: Not R-ISS stage I or III
- Stage III: ISS stage III and either high-risk CA by iFISH or high LDH
- [1]Palumbo A et al.: Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2015 September 10, 33 (26): 2863-9